Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2023-05-22 Board/Management Inform…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Directorate Change
Board/Management Information Classification · 1% confidence The document is a formal announcement disseminated via RNS (Regulatory News Service) regarding the appointment of a new Non-Executive Director, Anna Manz, to the Board of AstraZeneca PLC, effective September 1, 2023. This content directly relates to changes in the company's board of directors and senior management structure. This aligns perfectly with the definition for Board/Management Information (MANG). Although it is distributed via RNS, the specific content is not a general regulatory filing but a specific management change announcement.
2023-05-22 English
TAGRISSO PLUS CHEMO IMPROVED PFS IN LUNG CANCER
Foreign Filer Report
2023-05-17 English
Tagrisso plus chemo improved PFS in lung cancer
Earnings Release Classification · 1% confidence The document begins with 'RNS Number : 6416Z' and is dated '17 May 2023'. It details positive clinical trial results (FLAURA2 Phase III trial) for a drug (Tagrisso) and includes quotes from R&D executives and medical investigators. The content is a press release announcing significant scientific/business developments, not a formal regulatory filing like a 10-K or a short announcement of a report. This structure strongly aligns with an Earnings Release (ER) or a general announcement. Since it focuses on clinical trial data and product updates rather than quarterly financial figures (which would suggest ER), and it is not a short notice about another report (RPA), it fits best as a general announcement of material information. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a detailed, non-financial, material news announcement distributed via the RNS system that doesn't fit a more specific category like M&A (TAR) or Capital Change (CAP). However, the content is very similar to what is often included in an Earnings Release (ER) when companies discuss pipeline progress alongside financial results, but since no actual financial figures are present, RNS is the safest classification for a detailed clinical update distributed via the RNS service. Q2 2023
2023-05-17 English
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2023-05-09 English
FARXIGA EXTENDED IN THE US FOR HEART FAILURE
Foreign Filer Report
2023-05-09 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is an official notification released via RNS (London Stock Exchange news service) detailing a 'Transaction by Person Discharging Managerial Responsibilities (PDMR)'. Specifically, it reports the 'Sale of ADSs' by the Chief Financial Officer, Aradhana Sarin, on a specific date (May 5, 2023). This perfectly matches the definition of a Director's Dealing report, which tracks personal share transactions by company directors and executives (insider trades). The corresponding code is DIRS.
2023-05-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.